|
Comparing EDTA I.V. Chelation
and TriCardia
Basically, the only advantage of I.V. administered EDTA over
that of oral administration is that of initial speed. I.V.
EDTA will immediately enter the bloodstream whereas orally
administered EDTA will take at least 20 minutes to an hour
before EDTA will be fully absorbed, as the gut will buffer
the amounts of EDTA entering the bloodstream, ensuring a slow
and even assimilation. (Please note: Oral administration of
EDTA is, in fact, much like the slow and even assimilation
provided by the drip of an I.V. administration; it just takes
a few minutes longer to get into the bloodstream.)
Also I.V. administration
will ensure that EDTA will not be used for other purposes
in the body and will be primarily available for immediate
chelation in the circulation. However, within 30 minutes (and
perhaps sooner), I.V. chelated EDTA will begin to circulate
to other areas of the body wherein molecular competition (similar
to that of orally consumed EDTA) will be experienced. Other
than that, there is no known nor scientifically proven advantage
of I.V. administered EDTA over that of orally administered
EDTA.
Thus, as is with other Free
Form Amino Acids, when EDTA is taken orally, it should be
with other Free Form Amino Acids to ensure that biochemical
competition (such as transamination occurring within the liver)
is minimized and reduced, not only upon consumption, but later
within the bloodstream, so as to keep EDTA populations in
Free Form and at a maximum. Indeed, for this very reason,
I.V. formulas could be improved greatly with the addition
of other Free Form Amino Acids.
TriCardia can be used safely
with I.V. Chelation, as an additional agent of chelation as
well as to provide additional help of buffering the body from
chelation results. But, TriCardia has additional benefits
offered over and above I.V. Chelation alone, namely the detoxifying
of the liver and kidneys. Normal I.V. Chelation does not cleanse
the liver or the kidneys, the filters of the cardiovascular
system, whereas TriCardia does.
Despite the power of EDTA
I.V. Chelation, it is only effective in removing some (not
all) heavy metals from the bloodstream. EDTA is most attracted
to metals and heavy ionic metallic minerals which have a double
valency, such as lead and calcium. I.V. Chelation does not
and will not remove all toxic elements and metals from the
cardiovascular system.
However, TriCardia offers
not only safe amounts of EDTA, but 31 Free Form Amino Acids
(e.g. L-Cysteine) which help chelate other excess toxic metal
possibilities such as nickel, tin, zinc and copper more efficiently
from the system. L-Glutathione in particular alters the action
of dangerous peroxides, and has also been recently shown to
be an effective agent against the HIV-1 virus, as well as
help in removing dangerous excesses of homecysteine from the
body. In general, most I.V. Chelation formulas are not as
sophisticated nor as broad a spectrum as TriCardia and do
not have the elements which would create such safety and power.
Furthermore, the additional nutraceuticals in TriCardia help
the body rid itself of toxins faster and more efficiently
than I.V. Chelation alone.
EDTA I.V. Chelation is only
effective in removing free (not bound or attached) heavy metals
and minerals from the bloodstream. It cannot, and will not,
ever breakdown or dissolve cholesterol- calcified plaque as
some imagine. By itself, it is useless against the cholesterol
plaque already formed and lining the veins and arteries of
our cardiovascular system. The reason is that EDTA as a chelating
agent can only attach itself to unattached or free metals
and minerals in the bloodstream. EDTA cannot attach itself
to the calcium or lead which is bound to the walls of veins
or arteries.
But unlike I.V. Chelation,
TriCardia contains a complex of buffering agents, safe and
all natural ingredients, which by themselves, have been shown
to help the body naturally dissolve calcified acidic plaque.
Once dissolved, the chelating agents found within TriCardia
can then naturally grab onto the now freed metals and minerals,
removing them safely from the cardiovascular system. This
breakdown of plaque can be increased by further buffering
with other alkalizing agents, such as those found within VÄXA's
Buffer-pH. It is known that by decreasing systemic acidic
values, calcification can be slowly and safely dissolved over
time.
Although I.V. administered
EDTA can help kidney function by removing heavy metals, and
thus indirectly increase the efficiency of circulation and
ionic distribution within the kidney, it does not address
other nutritional support problems of the kidneys and liver
as does TriCardia. The other natural ingredients within TriCardia,
along with EDTA, will similarly help the body to naturally
improve circulation and ionic balance within the kidneys.
But TriCardia contains specific phytomedicinals, which ingredients
by themselves have been shown to help the body quickly and
effectively dissolve calcified stones and other toxic and
unhealthy debris which may collect within the kidneys (and
the gall bladder), while detoxifying the liver, allowing these
materials to harmlessly and painlessly pass from the system
as well. I.V. Chelation formulas do not offer this advantage.
Lastly, TriCardia contains
a chorded blend of micro-nutritionals and glycosaminoglycans
which possess natural abilities to specifically help the body
to regenerate and heal the overly stressed, traumatized and
damaged tissues of the cardiovascular system, liver and kidneys.
I.V. Chelation has little, if any, initiatory nutritional
support powers of cellular regeneration.
The result is that due
to the additional strengths of TriCardia, which are not offered
by I.V. Chelation alone, many Chelationists are now successfully
complementing I.V. Chelation Therapies (which have a limited
range of activity) with the Oral Chelation and Detoxifying
powers of TriCardia.
Dosage of EDTA
in TriCardia
A full daily dose of TriCardia (12 capsules) contains 1.5
grams of EDTA, buffered within a combination of 31 other Free
Form Amino Acids and other buffering compounds, as well as
the full spectrum of mineral ascorbates, phytomedicinals and
free radical and heavy metal scavengers.
The Results of
Oral and I. V. Chelation
Appropriate buffered Chelation, which not only removes heavy
metals from the body, but helps in the dissolution of calcified
plaque within the cardiovascular system should, overtime,
improve circulation tremendously. Both Oral and I.V. Chelation
seem very effective, and may have synergistic results when
used together. Remember, chelation by itself is a process
which is a natural function of the body systemically. Increasing
the population of chelating agents, either by oral or I.V.
means, can only enhance the effectiveness of chelation in
the long run.
Medical texts estimate
that an increase in just 1mm in diameter of the lumen within
veins and arteries will permit a 4-fold increase in blood
flow! Such an increase allows fresh oxygenated blood and nutrients
to efficiently feed all the cells of the body, as well as
aid in the speedy removal of all waste products coming from
those cells. Such a cleansing can aid in the recovery and
treatment of a number of diseases including:
1- Cardiovascular
Disease (including Arteriosclerosis, Heart Attack, Stroke,
High Cholesterol, High Blood Pressure)
2- All Forms
of Cancer
3- Diabetes
and Obesity
4- Neurological
diseases including MS, MD, ALS and Parkinson's
5- Liver and
Kidney disease
6- Senility,
Dementia and Alzheimer's
7- Immune
Deficiencies
8- Osteoporosis
and Tooth Loss
9- Hormonal
Imbalances and Premature Aging
References:
Reynolds,
J.E.F., (ed), Martindale, The Extra Pharmacopoeia, Royal Pharmaceutical
Society, London, 31st Edition, 1996, 981-981.
Grier MT,
Meyers, D.G., So much writing, so little science: a review
of 37 years of literature on ededate sodium chelation therapy,
Annuals of Pharmacotherapy, 1993, 18: 1000-3.
Fouque,
D., and Kopple, J.D., Total Parenteral Nutrition and Its Complications,
in Arieff, Allen I., and DeFronzo, Ralph, A., (Editors) Fluid,
Electrolyte and Acid-Base Disorders, Churchill Livingstone,
New York, NY, 1995.
Jones,
J., Amino Acid and Peptide Synthesis, Oxford University Press,
Oxford, 1992.
Cynober,
L.A., Amino Acid Metabolism and Therapy and Nutritional Disease,
CRC Press, Boco Raton, FL., 1995.
Lehninger,
A.L., Nelson, D.L. and Cox, M.M., Principles of Biochemistry,
Worth Publishers, New York, NY, 1993.
Linder,
M.C., Editor, Nutritional Biochemistry and Metabolism with
Clinical Applications, Appelton & Lange, Norwalk, CT,
1991.
Freidman,
Mendel, Absorption and Utilization of Amino Acids, Vol. I,II,III,
CRC Press, Boca Raton, FL., 1989.
Patton,
K.T., Thibodeau, Gary G., Anatomy & Physiology, Third
Edition, Mosby, St. Louis, MO. 1996.
Weatherall,
D.J., Ledingham, J.G.G., Warrell, D.A., (Editors), Oxford
Textbook of Medicine, Volumes 1,2 & 3, Oxford University
Press, Oxford, England, 1996.
Windhorst,
U., Regulatory Principles in Physiology, in Greger, R., and
Windhorst, U., (Editors), Comprehensive Human Physiology,
Volume 1 & 2, Springer Publishing, New York and Heidleberg,
1996.
Palamara,
A.T., Perno, C.F., Aquaro, S., Bue, M.C., Dini, L., Garaci,
E., Glutathione inhibits HIV replication by acting at late
stages of the virus life cycle. AIDS Res Hum Retroviruses
1996 Nov 1;12(16):1537-41.
Coronary
Heart Disease, Supplement to the Lancet, Lancet, 348, (suppl
I), 1-21, 1996.
Herzenberg,
L.A., De Rosa, S.C., Dubs, J.G., Roederer, M., Anderson, M.T.,
Ela, S.W., Deresinski, S.C., Herzenberg, L.A., Glutathione
deficiency is associated with impaired survival in HIV disease.
Proc Natl Acad Sci U S A 1997 Mar 4;94(5):1967-72.
Sachan,
A.S., Kannan, G.M., Kumar, P., Flora, S.J., Effects of chelation
therapy on hepatic glutathione, lipid peroxidation and phospholipid
contents in lead-poisoned rats, Indian J Physiol Pharmacol
1996 Apr;40(2):180-2.
Ali, M.S.,
Quadri, S.M., Maleimido derivatives of diethylenetriaminepentaacetic
acid and triethylenetetraaminehexaacetic acid: their synthesis
and potential for specific conjugation with biomolecules,
Bioconjug Chem 1996 Sep-Oct;7(5):576-83.
Chappell,
L.T., Janson, M., EDTA chelation therapy in the treatment
of vascular disease, J Cardiovasc Nurs 1996 Apr;10(3):78-86,
and comment in: J Cardiovasc Nurs 1996 Apr;10(3):v-x.
Eder, M.I.,
Miquel, J.F., Jongst, D., Paumgartner, G., von Ritter, C.,
Reactive oxygen metabolites promote cholesterol crystal formation
in model bile: role of lipid peroxidation, Free Radic Biol
Med 1996;20(5):743-9.
Tandon,
S.K., Singh, S., Flora, S.J., Influence of methionine and
zinc supplementation during chelation of lead in rats. J Trace
Elem Electrolytes Health Dis 1994 Jun;8(2):75-7.
Tandon,
S.K., Singh, S., Jain, V.K., Efficacy of combined chelation
in lead intoxication. Chem Res Toxicol 1994 Sep-Oct;7(5):585-9.
Tomita,
M., Hayashi, M., Awazu, S., Absorption-enhancing mechanism
of EDTA, caprate, and decanoylcarnitine in Caco-2 cells.J
Pharm Sci 1996 Jun;85(6):608-11.
Janson,
M., "Combining Chelation and Nutrition Therapy for Vascular
Disease," 1996 Dec. Nut Science News |
